RA0064

antibody from Oursmab

Targeting: CCR2 CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0064

Provider

Oursmab

Product name

Plozalizumab (Biosimilar Reference Antibody) (CCR2)

Antibody type

Monoclonal

Description

Plozalizumab (also known as MLN-1202) is a humanized IgG1 kappa monoclonal antibody developed as a targeted immunomodulatory therapy. It specifically binds with high affinity to the C-C chemokine receptor type 2 (CCR2). By blocking this receptor, plozalizumab inhibits the primary signaling pathway responsible for the recruitment of monocytes and macrophages from the bloodstream into inflamed tissues. This mechanism of action aims to reduce the pathogenic infiltration and activation of these immune cells at disease sites, positioning it as a potential therapeutic agent for conditions driven by chronic inflammation, such as atherosclerosis, rheumatoid arthritis, diabetic nephropathy, and other inflammatory disorders.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.